Koji Tokoyoda

Title: Koji Tokoyoda: Innovator in Gene Therapy

Introduction

Koji Tokoyoda is a prominent inventor based in Berlin, Germany. He has made significant contributions to the field of gene therapy, particularly in the manipulation of long-lived plasma cells. His innovative work has the potential to impact the treatment of diseases associated with these cells.

Latest Patents

Koji Tokoyoda holds a patent for derived peptides aimed at manipulating long-lived plasma cells. The patent describes an isolated polypeptide that includes the amino acid sequence EEAEKAKEAAEKALNEAFE or a sequence with at least 70%, 80%, or 90% identity to it. This polypeptide is no longer than 200 or 170 amino acids. Additionally, a nucleic acid encodes the polypeptide, and a gene therapy vector includes this nucleic acid. Genetically modified cells can express the polypeptide, which can be utilized for treating diseases associated with pathogenic long-lived plasma cells. He has 1 patent to his name.

Career Highlights

Koji Tokoyoda is affiliated with the Deutsches Rheuma-Forschungszentrum Berlin, where he conducts his research and development. His work focuses on advancing the understanding and treatment of diseases related to plasma cells.

Collaborations

One of his notable collaborators is Akiko Takaya, with whom he has worked on various projects in the field of gene therapy.

Conclusion

Koji Tokoyoda's innovative contributions to gene therapy and his patent on derived peptides highlight his role as a key figure in advancing medical science. His work continues to pave the way for new treatments for diseases associated with long-lived plasma cells.